Abstract
Objective:
To review the efficacy, safety, and clinical selection considerations of azole antifungal agents for prophylaxis of invasive fungal infections (IFIs) in immunocompromised patients using a clinically oriented, pharmacist-focused framework.
Data Sources:
A literature review was conducted using PubMed and Embase to identify relevant studies evaluating azole antifungal prophylaxis in immunocompromised adult populations. Search terms included combinations of “azole,” “antifungal prophylaxis,” “immunocompromised,” and “invasive fungal infection,” with emphasis on contemporary studies reflecting current prophylaxis practices.
Study Selection and Data Extraction:
Studies were included if they evaluated prophylactic use of azole antifungal agents in immunocompromised adults, including patients with hematologic malignancies, hematopoietic stem cell transplantation, or other defined immunocompromised states. Studies focused on treatment rather than prophylaxis, non-azole agents, pediatric populations, or lacking relevant clinical outcomes were excluded. Data extracted included study design, patient population, antifungal agent and dosing, incidence of IFIs, and reported safety outcomes.
Data Synthesis:
Randomized controlled trials and observational studies demonstrate that azole antifungal prophylaxis significantly reduces IFI incidence in high-risk immunocompromised populations. Posaconazole has demonstrated superiority over fluconazole and itraconazole in neutropenic leukemia populations, while mold-active azoles including voriconazole and isavuconazole offer expanded prophylactic options in select patients. Therapeutic drug monitoring, drug interaction management, and individualized risk stratification are critical pharmacist-driven components of care. Safety findings remain consistent with known azole-associated toxicities including hepatotoxicity, QT interval alterations, neuropsychiatric effects, and cytochrome P450-mediated drug interactions.
Conclusions:
Azole antifungal prophylaxis remains a cornerstone strategy for prevention of IFIs in immunocompromised patients. Current evidence supports individualized, risk-based selection of prophylactic agents based on patient-specific risk factors rather than universal application of a single regimen. Pharmacists play a central role in optimizing prophylaxis through therapeutic drug monitoring, medication reconciliation, and toxicity mitigation. Additional studies are needed to optimize prophylaxis strategies and improve patient outcomes.
Keywords
Get full access to this article
View all access options for this article.